Related Experiment Videos
Adjuvant therapy in operable pancreatic cancer
Swiss Surgery = Schweizer Chirurgie = Chirurgie Suisse = Chirurgia Svizzera
|May 17, 2002
Summary
Pancreatic cancer survival rates remain low despite surgical advances. This review examines adjuvant therapy trials, including EORTC and ESPAC studies, and explores future treatment options for pancreatic adenocarcinoma.
Area of Science:
- Oncology
- Gastroenterology
Background:
- Pancreatic adenocarcinoma is a highly lethal malignancy with poor survival rates.
- Despite surgical improvements, five-year survival post-resection remains below 20%.
Purpose of the Study:
- To review recent clinical trials investigating adjuvant therapy for pancreatic cancer.
- To discuss findings from EORTC and ESPAC studies and explore future treatment strategies.
Main Methods:
- Review of published clinical trials and studies on adjuvant therapy for pancreatic cancer.
- Analysis of results from European Organization for Research and Treatment of Cancer (EORTC) and European Study Group for Pancreatic Cancer (ESPAC) trials.
Main Results:
- Adjuvant chemoradiotherapy showed initial promise but requires further validation.
- Recent trials provide updated data on the efficacy and limitations of current adjuvant treatment protocols.
Conclusions:
- Current adjuvant therapies offer limited survival benefit for pancreatic cancer patients.
- Further research into novel treatment options is crucial to improve outcomes for pancreatic adenocarcinoma.